Cocrystal Pharma, Inc. Common Stock (COCP) is a publicly traded Healthcare sector company. As of May 21, 2026, COCP trades at $1.13 with a market cap of $16.27M and a P/E ratio of -1.42. COCP moved -2.61% today. Year to date, COCP is +1.83%; over the trailing twelve months it is -26.73%. Its 52-week range spans $0.86 to $3.26. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces COCP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cocrystal Pharma Enrolls Phase 1b CDI-988 Norovirus Cohort, Earns Fast Track Status: Cocrystal Pharma’s Phase 1b study of CDI-988 has fully enrolled its cohort testing GII.2 norovirus infectivity after Phase 1 showed safety and tolerability with no serious adverse events. CDI-988 targets the conserved 3CL protease, has Fast Track status and could address a $60 billion norovirus market with no approved therapies.
| Metric | Value |
|---|---|
| Price | $1.13 |
| Market Cap | $16.27M |
| P/E Ratio | -1.42 |
| EPS | $-0.78 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.26 |
| 52-Week Low | $0.86 |
| Volume | 25 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-8.83M |
| Gross Margin | 0.00% |
1 analysts cover COCP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.